Ladenburg Thalmann analyst Michael Higgins initiated coverage of Novavax with a Buy rating and $3 price target. The firm previously had a Buy rating on the shares with the same price target under analyst Kevin DeGeeter. Higgins looks for "transformational" data in Q1 of 2019. The company is developing ResVax, which could become the first vaccine against respiratory syncytial virus, a significant health concern for both infants and older adults, the analyst tells investors in a research note. He points out that Novavax is also developing a "potent" non-egg-based flu vaccine called NanoFlu that he believes could become the new standard of care. The company is approaching a "major turning point" with both pivotal RSV vaccine data and Phase 2 NanoFlu data expected in Q1, says Higgins.